&lt;p&gt;Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with &lt;em&gt;EGFR&lt;/em&gt;-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program&lt;/p&gt;

Tu, Hai‐Yan; Wu, Yi‐Long

doi:10.2147/ott.s273866

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dose de-escalation was recorded in 24 patients (26.7%) in this study. A previous study suggested that afatinib dose adjustments are acceptable in clinical practice and do not affect the efficacy of afatinib in advanced EGFR-mutated NSCLC patients [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

et al. 2023

View full text Add to dashboard Cite

Background Real-world clinical experience with afatinib as a treatment for advanced lung adenocarcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations (G719X, L861Q and S768I) has rarely been reported. Objective We aimed to perform a retrospective multicenter study to analyze afatinib therapy in untreated advanced lung adenocarcinoma harboring uncommon EGFR mutations. Patients and Methods Between May 2014 and June 2021, the data of 90 stage IIIB/IV lung adenocarcinoma patients with uncommon EGFR mutations (G719X/L861Q/S768I) treated with first-line afatinib from the cancer center database of Linkou, Tucheng, and Kaohsiung Chang Gung Memorial Hospitals were retrospectively retrieved and analyzed. Results Afatinib had an objective response rate (ORR) of 63.3% and a disease control rate (DCR) of 86.7%. The median progression-free survival (PFS) with first-line afatinib therapy was 17.3 months (95% confidence interval (CI), 12.07-22.53), and the median overall survival (OS) was 28.5 months (95% CI,) in all study patients. In the multivariate analysis, poor performance (Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2) and brain and liver metastases were independent predictors of unfavorable PFS. The G719X mutation (alone+compound) was an independent predictor of favorable PFS (hazard ratio (HR) = 0.578; 95% CI, 0.355−0.941; P = 0.027). Most afatinib-related adverse events (AEs) were limited to grades 1 and 2 and were manageable.

show abstract

Section: Discussionmentioning

confidence: 99%

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Notably, TTF was significantly longer in patients with dose modification than in those without modification in this study. Previous studies have reported equivalent or better responses and clinical outcomes in patients with LUAD with dose reduction during afatinib treatment [22,23]; however, no studies have explored such association in LSCC. Our findings were in line with the prior results on LUAD and prove that active dose modification during afatinib treatment can also be beneficial in LSCC.…”

Section: Discussionmentioning

confidence: 98%

Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study)

Ji,

Oh,

Park

et al. 2023

Cancers

View full text Add to dashboard Cite

This study aimed to evaluate treatment outcomes and safety of afatinib in patients with squamous cell carcinoma of the lung (LSCC) who progressed after chemotherapy and immunotherapy. We recruited patients both retrospectively and prospectively and collected the outcomes and safety data. Additionally, we performed next-generation sequencing using tumor tissue and/or plasma to explore potential molecular biomarkers. Altogether, 42 patients were included in the final analysis. The median number of prior treatments was three (range 1–8), and the median TTF was 2.1 months. Objective response rate and disease control rate were 16.2% and 59.5%, respectively, and median duration of response was 4.0 months among response evaluable patients (n = 37). Treatment-related adverse events (TRAEs, including diarrhea, stomatitis, and paronychia) occurred in 22 (52.3%) patients; however, most were grade 2 or lower, and only 5 cases were grade 3. TRAEs led to dose modification in 17 (40.5%) and discontinuation in 4 (9.5%) patients. The TTF in patients with ERBB2 mutations was significantly longer than that in patients without (6.8 vs. 2.1 months, p = 0.045). Our results highlight that afatinib is a reasonable treatment option in terms of effectiveness and safety, and ERBB2 mutation can be used as a predictive biomarker in clinical settings.

show abstract

“…The association between the performance status and the occurrence of adverse effects could be related to both hypoproteinemia as well as weight loss. While EGFR-TKI is usually prescribed with fixed dosage, there are proposed ways of dose reduction for patients with low body weight or body mass index, and this may improve tolerance to treatment (19,(22)(23)(24)(25). As dose reduction was a commonly acceptable option to manage adverse effects, pre-emptive dose reduction may be a reasonable option for patients with plasma hypoproteinemia or suboptimal performance status.…”

Section: Discussionmentioning

confidence: 99%

Serum protein level as a predictor of therapeutic response and adverse effects associated with afatinib use

Kwok

Tam

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

show abstract

<p>Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with <em>EGFR</em>-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program</p>

Cited by 4 publications

References 29 publications

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study)

Serum protein level as a predictor of therapeutic response and adverse effects associated with afatinib use

Contact Info

Product

Resources

About